(Q84326145)

English

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

scientific article published on 10 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

pharmacokinetics

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Beatriz Pardo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ramón Salazar

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Hernán Cortés-Funes

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Margarita García

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Margarita Majem

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ana Montes

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Carmen Cuadra

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Arturo Soto-Matos

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Claudia Lebedinsky

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Luis Paz-Ares

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

10 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

2240-2250

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660618%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

https://scigraph.springernature.com/pub.10.1007/s12032-011-9979-8

0 references

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of anticancer agents in patients with impaired liver function

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/21660618

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84326145&oldid=2144543011"